According to results of the STRATUS study, patients with refractory myeloma, oral pomalidomide significantly extends overall and progression-free survival, according to data from the largest study ever conducted in this population. Objective response rates to the regimen, which was well tolerated, were substantial even though the heavily pretreated patients were generally refractory to other novel agents. “These data confirm that pomalidomide plus low-dose dexamethasone is a standard of care for refractory multiple myeloma patients who have failed lenalidomide and bortezomib,” said Meletios A. Dimopoulos, MD, the chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, in Greece. He presented the results of the SATRATUS study at the 2014 ASH. For more information on the study and its recommendations, visit Clinical Oncology News and The International Myeloma Foundation.